| Original language | English (US) |
|---|---|
| Pages (from-to) | E008090 |
| Journal | Circulation: Heart Failure |
| Volume | 14 |
| Issue number | 3 |
| DOIs |
|
| State | Published - Mar 1 2021 |
Keywords
- diuretics
- heart failure
- prevalence
- thiazide
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Circulation: Heart Failure, Vol. 14, No. 3, 01.03.2021, p. E008090.
Research output: Contribution to journal › Comment/debate › peer-review
TY - JOUR
T1 - Could a Low-Dose Diuretic Polypill Improve Outcomes in Heart Failure With Preserved Ejection Fraction?
AU - Khan, Sadiya S.
AU - Huffman, Mark D.
AU - Shah, Sanjiv J.
N1 - Funding Information: Dr Huffman has received support from the American Heart Association, Verily, and AstraZeneca for work unrelated to this research. The George Institute for Global Health has a patent, license, and has received investment funding with intent to commercialize fixed-dose combination therapy through its social enterprise business, George Medicines. Dr Shah has received research grants from Actelion, AstraZeneca, Corvia, Novartis, and Pfizer and has served as a consultant, scientific advisory board member, and/or executive committee/steering committee member for Abbott, Actelion, AstraZeneca, Amgen, Axon Therapeutics, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Cardiora, CVRx, Cytokinetics, Eisai, GSK, Ionis, Ironwood, Merck, MyoKardia, Novartis, Pfizer, Sanofi, Shifamed, Tenax, and United Therapeutics. The authors plan to submit a patent for a polypill. Funding Information: This study was supported by grants from the National Institutes of Health (KL2TR001424, P30AG059988; P30DK092939) and the American Heart Association (#19TPA34890060) to Dr Khan. Research reported in this publication was supported, in part, by the National Institutes of Health’s National Center for Advancing Translational Sciences, Grant Number KL2TR001424 (Dr Khan). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Dr Shah is supported by grants from the National Institutes of Health (R01 HL107577, R01 HL127028, R01 HL140731, and R01 HL149423) and the American Heart Association (#16SFRN28780016).
PY - 2021/3/1
Y1 - 2021/3/1
KW - diuretics
KW - heart failure
KW - prevalence
KW - thiazide
UR - http://www.scopus.com/inward/record.url?scp=85103227317&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103227317&partnerID=8YFLogxK
U2 - 10.1161/CIRCHEARTFAILURE.120.008090
DO - 10.1161/CIRCHEARTFAILURE.120.008090
M3 - Comment/debate
C2 - 33663231
AN - SCOPUS:85103227317
SN - 1941-3289
VL - 14
SP - E008090
JO - Circulation: Heart Failure
JF - Circulation: Heart Failure
IS - 3
ER -